• Markets
    • icon
  • Companies
CHM · ASX

Chimeric Therapeutics Limited (ASX:CHM)

AU$0.015

 0.0 (0.0%)
ASX:Live
06/09/2024 04:10:33 PM
Near Support Near 52 Week Low HALO Ords GROWTH AUS All-Consensus +1
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

CHM Overview

CHM Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Strong

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About CHM

Website

N/A

Telephone

61.3.9824.5254

Address

Level 3 62 Lygon Street Carlton, Victoria (VIC) 3053

Description

Chimeric Therapeutics Ltd. is a clinical stage cell therapy company, which engages in the development and commercialization of cell therapies in oncology. Its products include NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company was founded by Paul A. Hopper in 2020 and is headquartered in Carlton South, Australia.

CHM Price Chart

Key Stats

Market Cap

AU$14.30M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.01 - 0.05

Trade Value (12mth)

AU$16,299.00

1 week

-11.76%

1 month

-25%

YTD

-58.33%

1 year

-54.55%

All time high

0.42

Key Fundamentals

EPS 3 yr Growth

-77.50%

EBITDA Margin

N/A

Operating Cashflow

-$8m

Free Cash Flow Return

0.00%

ROIC

0.00%

Interest Coverage

-62.40

Quick Ratio

0.00

Other Data

Shares on Issue (Fully Dilluted)

N/A

HALO Sector

Healthcare

Next Company Report Date

27-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

CHM Announcements

Latest Announcements

Date Announcements

30 August 24

Appendix 4E and Preliminary Final Report

×

Appendix 4E and Preliminary Final Report

30 August 24

Application for quotation of securities - CHM

×

Application for quotation of securities - CHM

30 August 24

Notification regarding unquoted securities - CHM

×

Notification regarding unquoted securities - CHM

30 August 24

Notice under section 708A

×

Notice under section 708A

28 August 24

First patient dosed in Phase 1/2 trial of CHM CDH17

×

First patient dosed in Phase 1/2 trial of CHM CDH17

16 August 24

Phase 1/2 CHM CDH17 CAR-T GMP Manufacturing Complete

×

Phase 1/2 CHM CDH17 CAR-T GMP Manufacturing Complete

13 August 24

Chimeric receives $1.5 M advance on FY24 R&D tax incentive

×

Chimeric receives $1.5 M advance on FY24 R&D tax incentive

09 August 24

Chimeric partnering with Cell Therapies Australia

×

Chimeric partnering with Cell Therapies Australia

02 August 24

Application for quotation of securities - CHM

×

Application for quotation of securities - CHM

02 August 24

Notice under section 708A

×

Notice under section 708A

31 July 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

25 July 24

Investor Presentation

×

Investor Presentation

22 July 24

First patient enrolled in CHM CDH17 Phase 1/2 clinical trial

×

First patient enrolled in CHM CDH17 Phase 1/2 clinical trial

28 June 24

Application for quotation of securities - CHM

×

Application for quotation of securities - CHM

28 June 24

Notice under section 708A

×

Notice under section 708A

26 June 24

Notification of cessation of securities - CHM

×

Notification of cessation of securities - CHM

11 June 24

Presentation to Extraordinary General Meeting

×

Presentation to Extraordinary General Meeting

11 June 24

Results of Meeting

×

Results of Meeting

05 June 24

Phase 1b ADVENT-AML trial of CHM CORE-NK advances at MDA

×

Phase 1b ADVENT-AML trial of CHM CORE-NK advances at MDA

30 May 24

Application for quotation of securities - CHM

×

Application for quotation of securities - CHM

30 May 24

Notice under section 708A

×

Notice under section 708A

30 May 24

Final Director's Interest Notice

×

Final Director's Interest Notice

22 May 24

Chimeric opens CHM CDH17 Phase 1/2 trial

×

Chimeric opens CHM CDH17 Phase 1/2 trial

20 May 24

CHM CDH17 Phase 1/2 clinical trial approved for initiation

×

CHM CDH17 Phase 1/2 clinical trial approved for initiation

16 May 24

CHM CORE-NK vactosertib Phase 1b study re-opens enrolment

×

CHM CORE-NK vactosertib Phase 1b study re-opens enrolment

CHM Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.04 -0.06 -0.02 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.04 -0.06 -0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock 44.8 -35.3 69.9 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.03 -0.04 -0.01 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.04 -0.04 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 21.0 -54.7 78.3 Lock Lock Lock
     Yield % Lock Lock Lock Lock -39.8 -99.1 0.0 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.06 0.01 0.00 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.03 -0.01 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -13.9 -151.0 24.6 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 360 433 696 Lock Lock Lock
Basic m Lock Lock Lock Lock 360 433 696 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 14 29 21 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -1 -1 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -12.1 -1.6 99.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -14 -29 -21 Lock Lock Lock
     Growth % Lock Lock Lock Lock 2.7 -109.4 27.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 1 1 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -15 -29 -21 Lock Lock Lock
     Growth % Lock Lock Lock Lock 1.8 -102.3 29.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -16 -30 -21 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 -4 -9 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -16 -26 -13 Lock Lock Lock
     Growth % Lock Lock Lock Lock -5.2 -63.0 51.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -13 -16 -8 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 1 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -1 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 10 0 8 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -13 -16 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -48.6 -23.9 100.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 18 5 3 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 35 22 15 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -18 -5 0 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 9 17 13 Lock Lock Lock
Equity $m Lock Lock Lock Lock 26 6 2 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 26 6 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 2.3 -78.0 -100.0 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -45.6 -115.8 -82.0 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -61.8 -457.8 -507.3 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -57.3 -188.0 0.0 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -62.5 -165.2 0.0 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -51.7 -104.0 0.0 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -21.3 -36.9 -62.4 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.3 0.2 0.0 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -71.5 -94.9 0.0 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 2.3 0.6 0.3 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 2.3 0.6 0.0 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 86.8 57.4 94.8 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -145.8 -111.1 -74.8 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -45.6 -115.8 -82.0 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.4 4.0 6.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -61.8 -457.8 -507.3 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -61.8 -457.8 -507.3 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 1,295.2 2,289.8 0.0 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -1,295.2 -2,289.8 0.0 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

CHM Shortsell

Frequently Asked Questions

The current share price of Chimeric Therapeutics Limited (CHM:ASX) is AU$0.015.
The 52-week high share price for Chimeric Therapeutics Limited (CHM:ASX) is AU$0.05.
The 52-week low share price for Chimeric Therapeutics Limited (CHM:ASX)? is AU$0.01.
Chimeric Therapeutics Limited (CHM:ASX) does not pay a dividend.
Chimeric Therapeutics Limited (CHM:ASX) does not pay a dividend.
Chimeric Therapeutics Limited (CHM:ASX) has a franking level of 0.0%.
Chimeric Therapeutics Limited (CHM:ASX) is classified in the Healthcare.
The current P/E ratio for Chimeric Therapeutics Limited (CHM:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.